Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I thinks Tils is very good at not showing there cards, as per NDA’s, all said in public. Could happen tomorrow, next week, next month etc etc. We have a potential major catalyst in the next few weeks, as said. Could be an exceptable offer on good pharmokenetics results or partnership or licensing, we don’t know but we do have the cash to move forward without that (Phew). Can land at anytime GLA.
I agree.Unless tils get on the fast track phase 1 trials government program (
i think somebody mentioned it a few weeks back), the covid "hype" phase (tlsa being confused with tesla or whatever) is probably over for now (who knows the eventual twists and turns with covid).
Thus, tils is a longer term play (although there could be a preclinical licencing option, but i don't think the bod and main shareholder would want that) and however good the potential it will take time to realise it as in normal times with pharma.I doubt there will be big partners until at least after a phase 1/2 trial at least as there are still too many unknowns.That's the big reward eventually with small caps if they work out and it takes a long time and patience often!
Did you contact tils pr with your question or the company directly?
Well said Shiraz. !
Has everyone forgot the whole world is going through a pandemic ? It is quite possible that members of the BOD are suffering from Long COVID
Baffling sometimes SK. It would seem the posters on this board believe, I mean GENUINELY BELIEVE, that a company like TILS will be bringing in a product overnight. A reflection on the current populations need for instant gratification. Doc K gives all these interviews on the technology repeating the same thing, not as a "rehash" as some say, but more as a hope that everyone will actually listen to what is said and consider what that means scientifically. Commercialisation is great and obviously required but not until phase III is well underway or even concluded. Honestly baffled. And they'll say $250m cash raise option at minimum (that's right MINIMUM) £1.50 a share doesn't ooze confidence. I need to stop reading this board as it winds me up!
Its funny seeing everyone bashing the share. The fact is tils has been my least worst performing share over the last 2-3 weeks. Everything else is about 30% down due to worries about rising bond yield across the pond. Im guessing all the other posters on here must be hugely up on their portfolios apart from tils. If so good luck, sell up
Here and invest everything you have in those shares. If they continue to gain 300-400% over the next few months then let me know too and i can quit my job, sell up tils and join you, and perhaps buy a yacht in the Bahamas while Im at it. For now il continue to take my chances with tils. GLA
Unfortunately RedChip's paid for Saturday broadcast slots will not be enough. In my view Tiziana should instead be focusing on the specialist Biopharma investment community in the United States and not the day-trader community.
Hopefully someone; someone right, will appreciate Dr. K's brimming enthusiasm, and take heed of him, someday.
All these seminars, webinars & announcements are rephrased, rehashed & repolished. Go new today Doc!!!1
Spinnaker, I'd not underestimate the value in building a strong portfolio of patents and novel I.P. It's much more cost effective than gearing up for full scale production and in the right situation it's not uncommon for a very large company to simply buy the whole lot lock, stock and barrel just for that portfolio alone. Failing that licencing opportunities could be valuable too.
I've a history of buying into small Bio research companies and many get taken out by the big pharmas and end up stateside I think the story here will be no different.
Thanks Greend for the response and I note your points. No excuse for not replying to emails if they are seeking to be taken seriously as a public company with a thought of joining the LSE main list. I await a share price spike on the release of the Brazil details however I am not sure that will do much, there was a bit of a spike when first RNS'd . Maybe there won't be any significant move until the next cash raise and the pumping starts but note that is not intended until 2023.
Maybe that's cynical but I think I may be here a fairly long time.
Best
Spinnaker
I agree with you on some of those Spinnaker...
Governance is poor...(as is communication) and
Accustem has been (very) poorly handled...
The business is still behaving in a pre-clinical way (imo), with small number of employees (some key personnel not employees e.g. Dr Weiner and trails through CRO's as you'd expect).
They've stated they are fully funded so cash doesn't seem to be an issue - (personally would rather they sought funding if it could expedite developments).
I don't agree on the point re patents and KS, I think it's GC who runs the show and he's a track record of commercialising so think that is definitely their focus, however don't get the impression they are seeking to do this rapidly (although seeing that improve in last 3-6 months).
I would have thought we'd see a spike when the Brazil data comes out (next couple of weeks?), so if you do want to jump ship, that might be the opportunity?
Oh dear. The longer I hold this share the more I feel that Dr K has no real interest in commercialisation and seems much more interested in research and acquiring patents. Everything remains at very early stage. The governance of the company is poor and he appears to have no adequately heavy hitters on the board so runs it as if it was his own private company. The total debacle over listings changing, ADRs and Accustem is indicative that there is no thought of proper process.
My mood is not enhanced by the fact that my recent email to the company remains unanswered. Not even an acknowledgement. I wrote asking whether he was intending to try and get government assistance with progressing Foralumab trials for Covid both here and in the states since both countries are looking for appropriate new treatments and are prepared to fully or partially fund them. However it appears maybe he isn't concerned about the product for Covid any more. If he was we would have been informed before now of the proposals he had for progressing the treatment through to authorisation. Also we seem to have been waiting a fair time for publication of the data from the P1 Brazil trial. If he thinks a tie up with a large Pharma is possible then it is even more important to show that you are able and intending to progress in any event. Such a plan, costed and prepared, enhances the negotiating strength of the company.
Any self funded Phase 2 trial might be 12 months before completion and may well require more cash, if of any significant size, bearing in mind the two other trials intended this year. The timing is probably so far in the future that the situation on Covid prevalence and other drugs coming to market is uncertain.
Obviously, my negative take is exacerbated by the dire SP performance and the fact that I am reluctant to crystallise my heavy losses. At one time I could have sold out with only a minor loss but not now unfortunately. There are some good propositions in the pipeline but following the last nine months history I can't see that the boss has the people around him to focus, target and achieve monetisation for any of the potential drugs over which there are patents.
Spinnaker